Abstract
Aging is the major known risk factor for the onset of neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD). Mitochondria play a central role in aging as mitochondrial dysfunction increases with age and produces harmful levels of reactive oxygen species which leads to cellular oxidative stress (free-radical theory of aging). Oxidative stress is highly damaging to cellular macromolecules and is also a major cause of the loss and impairment of neurons in neurodegenerative disorders. A growing body of evidence suggests that modulation of sirtuin activity and restricting calorie intake has a strong neuroprotective effect. SIRT1 induction by the use of pharmacological activators or by calorie restriction (CR) diet regimen has been shown to protect against neuronal loss and impairment in the cellular and animal models of AD and PD. Here, we review the current knowledge and recent data related to the role of sirtuins and CR in neurodegeneration and discuss the potential underlying signaling pathways of neuroprotection that might serve as attractive targets for the future therapeutic intervention of these age-related neurodegenerative diseases.
Keywords: Sirtuin, calorie restriction, resveratrol, neuroprotection, SIRT1, SIRT2, AD, PD, neurons, neurogenesis
Current Pharmaceutical Design
Title: Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Volume: 17 Issue: 31
Author(s): Sarika Srivastava and Marcia C. Haigis
Affiliation:
Keywords: Sirtuin, calorie restriction, resveratrol, neuroprotection, SIRT1, SIRT2, AD, PD, neurons, neurogenesis
Abstract: Aging is the major known risk factor for the onset of neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD). Mitochondria play a central role in aging as mitochondrial dysfunction increases with age and produces harmful levels of reactive oxygen species which leads to cellular oxidative stress (free-radical theory of aging). Oxidative stress is highly damaging to cellular macromolecules and is also a major cause of the loss and impairment of neurons in neurodegenerative disorders. A growing body of evidence suggests that modulation of sirtuin activity and restricting calorie intake has a strong neuroprotective effect. SIRT1 induction by the use of pharmacological activators or by calorie restriction (CR) diet regimen has been shown to protect against neuronal loss and impairment in the cellular and animal models of AD and PD. Here, we review the current knowledge and recent data related to the role of sirtuins and CR in neurodegeneration and discuss the potential underlying signaling pathways of neuroprotection that might serve as attractive targets for the future therapeutic intervention of these age-related neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Srivastava Sarika and C. Haigis Marcia, Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072526
DOI https://dx.doi.org/10.2174/138161211798072526 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kinetic Study on the Effects of Extremely Low Frequency Electromagnetic Field on Catalase, Cytochrome P450 and Inducible Nitric Oxide Synthase in Human HaCaT and THP-1 Cell Lines
CNS & Neurological Disorders - Drug Targets Lewy Bodies: A Spectator or Salient Killer?
CNS & Neurological Disorders - Drug Targets Current Research on Opioid Receptor Function
Current Drug Targets Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets Nicotinamide and its Pharmacological Properties for Clinical Therapy
Drug Design Reviews - Online (Discontinued) Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Traumatic Spinal Cord Injury Alters Angiogenic Factors and TGF-Beta1 that may Affect Vascular Recovery
Current Neurovascular Research Zinc Homeostasis-regulating Proteins: New Drug Targets for Triggering Cell Fate
Current Drug Targets Metabolic Stress and Inflammation: Implication in Treatment for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson’s Disease Associated Mutations
Current Protein & Peptide Science Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis
Current Medicinal Chemistry High Doses of In vitro Beta-carotene, Alpha-Tocopherol and Ascorbic Acid Induce Oxidative Stress and Secretion of IL-6 in Peripheral Blood Mononuclear Cells from Healthy Donors
Current Aging Science Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Editorial [Hot Topic: Ageing (Guest Editors: H.-P. Deigner and R. Kinscherf)]
Current Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Rational Design of Novel Potential p38α MAPK Inhibitors with Drug-like Properties Using Pharmacophore and Similarity-based Virtual Screening Procedures
Current Bioactive Compounds Inherent Aggregation Propensity of Flanking Residues Attached to Polyglutamines: Implication to Aggregation Inhibition
Protein & Peptide Letters Structurally Unprecedented Metabolites from Marine Sponges
Current Organic Chemistry Use of Speech Analyses within a Mobile Application for the Assessment of Cognitive Impairment in Elderly People
Current Alzheimer Research Was Phenserine a Failure or Were Investigators Mislead by Methods?
Current Alzheimer Research